Sign in
Taking people in United StatesPhase 1

Oxytocin nose spray for obstructive sleep apnea in people using CPAP

Tests oxytocin nasal spray in adults with sleep apnea who use CPAP.

Key facts

Who runs it
Vivek Jain
Where
Washington D.C., United StatesSee the site
Trial code
Registry title
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
Status
Recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
4 Mar 2019
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Oxytocin
  • Placebo
Record updated
4 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obstructive sleep apnea who use a CPAP breathing machine. It tests whether an oxytocin nose spray lowers the CPAP pressure needed during sleep.

Age
18 years or older
Sex
Men and women
Disease stage
Obstructive sleep apnea treated with CPAP
Earlier treatment
People must be willing and able to use CPAP for their sleep apnea.

Main reasons for not taking part

  • Not willing or not able to use CPAP
  • Other sleep disorders
  • Pregnant or breastfeeding women, or women who can get pregnant and will not use birth control during the whole study
  • Prisoners, or people held for treatment against their will
  • Unable to give consent, for example because of a language barrier

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Men or women 18 years of age or older

Who cannot take part

  • Presence of other sleep disorders
  • Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness
  • Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study
  • subjects not willing to or otherwise unable to use CPAP for treatment of OSA
  • Pregnant or breastfeeding women
  • Prisoners or subjects who are involuntarily incarcerated
  • Patients unable to give consent because of a language barrier, or other reason

Where in United States

  • Medical Faculty AssociatesWashington D.C., United StatesContact: Vivek Jain, MDTaking people

About the trial

What the trial wants to find out

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea.

Read full original descriptionShow less

This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

The 2 groups in the trial

  • Visit 1 RandomizationTreatment being tested

    At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.

    Treatment: Oxytocin and Placebo

  • Visit 2 Crossover RandomizationTreatment being tested

    At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.

    Treatment: Oxytocin and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Benefits of Oxytocin in OSA Patients Using CPAP
Plain-language title
Oxytocin nose spray for obstructive sleep apnea in people using CPAPGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
4 May 2026